Guía de recomendaciones para el manejo de brolucizumab / Guidance on brolucizumab management recommendations

Objetivo: Brolucizumab, un anti-VEGF de nueva generación, ha demostrado su eficacia y seguridad en la degeneración macular asociada a la edad neovascular exudativa (DMAEn) en los ensayos pivotales HAWK y HARRIER. Tras su comercialización, se han reportado eventos adversos relacionados con la inflamación intraocular no detectados previamente. Una revisión post hoc independiente de los ensayos pivotales cifra la tasa de inflamación intraocular (IIO) en el 4,6%. El objetivo de este trabajo es proponer una serie de recomendaciones para implementar el manejo de brolucizumab en la práctica clínica. Método: Las recomendaciones realizadas por los autores se han basado en su experiencia clínica y en la revisión crítica de: 1)los ensayos pivotales; 2)el análisis post hoc del Comité de Revisión de Seguridad, y 3)la literatura publicada. Resultados: En los ensayos pivotales, brolucizumab mostró ganancias funcionales sostenidas, resultados anatómicos superiores con intervalos entre inyecciones potencialmente más prolongados y un perfil de seguridad global bien tolerado. Los eventos adversos reportados tras la comercialización incluyen vasculitis retiniana y la oclusión vascular retiniana. De acuerdo con la información disponible, los expertos recomiendan: 1)descartar los perfiles de pacientes no recomendados (historial previo de IIO); 2)explorar al paciente antes de cada inyección para descartar la presencia de IIO activa; 3)monitorizar al paciente para detectar precozmente los signos de alerta, y 4)tratar de inmediato en el caso de que se desarrolle algún evento adverso. ConclusionesLos : eventos adversos reportados son poco frecuentes, pero pueden estar asociados con una pérdida severa e irreversible de agudeza visual. Las recomendaciones realizadas pretenden facilitar el manejo de brolucizumab en la práctica habitual de los retinólogos, garantizar la seguridad del paciente y, en caso de que se produzca alguno de los eventos adversos, minimizar su impacto sobre la visión. (AU)

Purpose: Brolucizumab, a new generation anti-VEGF, has demonstrated efficacy and safety in AMD in the pivotal HAWK and HARRIER trials. Post-marketing, previously undetected adverse events related to intraocular inflammation have been reported. An independent post hoc review of the pivotal trials puts the rate of intraocular inflammation (IOI) at 4.6%. The aim of this paper is to propose a set of recommendations for implementing the management of brolucizumab in clinical practice. Method: The recommendations made by the authors are based on their clinical experience and critical review of (i)the pivotal trials; (ii)the post-hoc analysis of the Safety Review Committee, and (iii)the published literature. Results: In the pivotal trials, brolucizumab showed sustained functional gains, superior anatomical outcomes with potentially longer intervals between injections and a well-tolerated overall safety profile. Adverse events reported post-marketing include retinal vasculitis and retinal vascular occlusion. Based on the available information, experts recommend (i)ruling out non-recommended patient profiles (prior history of ORI); (ii)screening the patient prior to each injection to rule out active IOI; (iii)monitoring the patient for early warning signs, and (iv)treating immediately should any adverse events develop. Conclusions: The adverse events reported are rare, but may be associated with severe and irreversible loss of visual acuity. The recommendations made are intended to facilitate the management of brolucizumab in the routine practice of retinologists, to ensure patient safety and, should any adverse events occur, to minimise their impact on vision. (AU)

Guidance on brolucizumab management recommendations.

PURPOSE: Brolucizumab, a new generation anti-VEGF, has demonstrated efficacy and safety in AMD in the pivotal HAWK and HARRIER trials. Post-marketing, previously undetected adverse events related to intraocular inflammation have been reported. An independent post hoc review of the pivotal trials puts the rate of IOI at 4.6%. The aim of this paper is to propose a set of recommendations for implementing the management of brolucizumab in clinical practice. METHODS: The recommendations made by the authors are based on their clinical experience, critical review of (i) the pivotal trials, the post-hoc analysis of the Safety Review Committee, (ii), and (iii) the published literature. RESULTS: In the pivotal trials, brolucizumab showed sustained functional gains, superior anatomical outcomes with potentially longer intervals between injections and a well-tolerated overall safety profile. Adverse events reported post-marketing include retinal vasculitis and retinal vascular occlusion. Based on the available information, experts recommend (i) ruling out non-recommended patient profiles (prior history of ORI), (ii) screening the patient prior to each injection to rule out active ORI, (iii) monitoring the patient for early warning signs, and (iv) treating immediately should any adverse events develop. CONCLUSIONS: The adverse events reported are rare, but may be associated with severe and irreversible loss of visual acuity. The recommendations made are intended to facilitate the management of brolucizumab in the routine practice of retinologists, to ensure patient safety and, should any adverse events occur, to minimise their impact on vision.

A new standardised nomenclature in ophthalmology: Criteria and quantitative evaluation indicators of medical procedures. / Nuevo nomenclátor estandarizado en oftalmología: Criterios e indicadores cuantitativos de baremación de actos médicos.

PURPOSE: To create a new list of medical procedures in ophthalmology based on the International Classification of Diseases ICD-9-CM. To establish the general principles that define criteria, quantitative indicators, and scales. To develop the algorithms needed to calculate fees for medical procedures. METHODS: The out-of-date processes were removed from the list, and new techniques were added, descriptors were modified, procedures with similar descriptions were grouped together, and others were relocated to other group according to surgical complexity conditions. The criteria to calculate the medical fees were defined: training and complexity (U), proficient responsibility (R), and health value (V), with their respective quantitative indicators: period of training necessary to master a technique, frequency of complications that worsen the preoperative situation, and days of incapacity for work due to the process. The Relative Value Unit (RVU) was defined as the score sum of R, V and U. The final fee per medical procedure was calculated as the product of the RVU by its unit cost and by the weighting coefficient (WC). RESULTS: A new catalogue was prepared with 161 medical procedures, grouped into consultations, diagnostic procedures (DX.PR), therapeutic procedures (TX.PR), and surgical interventions, increasing in complexity from group 0 to group 8. The following characters were described for each one of the procedures: OMC and ICD-9-MC code, descriptor term, group, proposed modification: no changes or minimums in the descriptors, grouping of acts by similar definitions, change of origin group, new procedures, and procedures removed. The indicators for assessment were also scored: U between 1-4 points, and R and V between 0-3 points. Using their sum, the number of RVUs per medical procedure (between 1 and 10) was calculated which, together with the unit cost of the RVU and the WC (between 0.05 and 1), will determine the final rate. CONCLUSIONS: The new standardised ophthalmological nomenclature updates and improves the old classification, adapting the procedures to the descriptors included in the ICD-9-CM, and incorporating all the new techniques. Additionally, the declaration of the general principles allows defining new criteria, quantitative indicators, rating scales, and algorithms to calculate fees for medical procedures.

Management of Wet Age-Related Macular Degeneration in Spain: Challenges for Treat and Extend Implementation in Routine Clinical Practice.

PURPOSE: To ascertain wet AMD (wAMD) management patterns in Spain. METHODS: A two-round Delphi study conducted through a questionnaire-based survey designed from literature review and validated by an independent Steering Committee. RESULTS: Forty-nine retina specialists experienced in wAMD participated by answering the two-round study questionnaire. Retina specialists are the main responsible for wAMD diagnosis and monitoring, including visits and associated procedures, with a median time per visit of 15 minutes. Standard treatment strategies are based on anti-VEGF administration, including standard loading dose administration followed by maintenance with aflibercept or ranibizumab (81% of patients). Although treat and extend (T&E) dosing strategy is considered as optimal for wAMD management (78% of the panelists), the main routine healthcare limitations (i.e., visits overload, reduced staff, short visit time, coordination issues, lack of facilities) conduct to self-defined "flexible" strategies, based on T&E and pro-re-nata (PRN) protocols. CONCLUSION: Proactive treatment patterns (T&E) are the preferred ones by the retina specialists in Spain. However, their proper implementation is difficult due to healthcare resource limitations, as well as organisation and logistic issues. The use of anti-VEGF agents with longer duration of action could facilitate the use of strict T&E approaches according to routine clinical practices.

Phaco-non-penetrating deep sclerectomy in ocular hypertension secondary to dexamethasone intravitreal implant. / Faco-esclerectomía profunda no perforante como tratamiento de la hipertensión ocular secundaria al implante intravítreo de dexametasona.

PURPOSE: To evaluate the characteristics and progression of patients treated with a 0.7mg dexamethasone intravitreal implant (Ozurdex®) and required glaucoma filtering surgery (phaco-non-penetrating deep sclerectomy) to control ocular hypertension (OHT). METHODS: A retrospective observational study including patients treated with Ozurdex® in a tertiary-care university hospital from May 2011 to April 2016. RESULTS: In five years of follow-up, 1.10% (4/363) of patients treated with 0.7mg dexamethasone intravitreal implant required phaco-non-penetrating deep sclerectomy (PNPDS) to control OHT refractory to topical treatment. All four patients started or increased previous antihypertensive topical treatment since the first dexamethasone intravitreal implant. Three or more dexamethasone intravitreal implants were injected in the four cases before intraocular pressure (IOP) became uncontrolled and PNPDS was performed. All four patients have a successfully controlled IOP without treatment after PNPDS. Two patients required additional treatment with dexamethasone intravitreal implants after PNPDS, maintaining IOP under control without treatment. CONCLUSIONS: To the best of our knowledge, this is the first study describing the successful results of PNPDS in OHT secondary to dexamethasone intravitreal implant. All four patients have achieved controlled IOP without treatment. Re-treatment with dexamethasone intravitreal implant in those patients who underwent PNPDS is also possible, and IOP remains controlled.

[Factors involved in the burden of the primary caregiver of cancer patients]. / Factores que intervienen en la sobrecarga del cuidador primario del paciente con cáncer.

OBJECTIVE: The aim of the study was to identify the factors involved between burden in the primary caregiver of cancer patients and their quality of life. MATERIAL AND METHODS: A cross-sectional study was conducted in a secondary level hospital on 100 primary caregivers of cancer patients. The level of burden was determined using the Zarit scale and the perception of quality of life using the World Health Organisation Quality of Life questionnaire. Quality of life was categorised as high or low and compared between groups according to their level of burden. Descriptive statistics were performed on the study variables, and differences between groups were analysed according to their level of burden. RESULTS: In assessing the overload, it was found that 31% of caregivers had burden. A good quality of life was perceived by 76% of caregivers, while the remaining 24% perceived it as poor. To identify association between these two variables Chi squared (X2) was used to determine whether there was any association between quality of life and overloading of the primary caregiver, giving a P≤.05. A Spearman correlation was also performed, obtaining an r-value of .321 with a P≤.05, finding a slightly positive correlation. CONCLUSIONS: The factors that have a bearing on a good quality of life despite having burden were: being married, dedicated to the home, and kinship (to be immediate family: spouse, parents and children). Conversely, the type of cancer, sleep hours, and hours of care influence the perception of a poor quality of life.

[New perspectives in the approach to central retinal vein occlusion]. / Nuevas perspectivas en el abordaje de la oclusión de vena central de la retiniana.

OBJECTIVE: The COPERNICUS and GALILEO trials were designed to evaluate the safety and efficacy of intravitreal injection of 2mg of aflibercept in the treatment of macular edema secondary to central retinal vein occlusion. MATERIAL AND METHOD: Two phase III randomized, double-masked trials: COPERNICUS in North America (188 patients) and galileo in Europe and Asia (177 patients). In COPERNICUS, the patients in the treatment group received monthly injections of 2mg aflibercept for 6 months and later continued with strict PRN treatment with monthly follow-up every 6 months and with a minimum of 3-monthly follow up for 1 year. Patients in the placebo group could receive treatment after the sixth month, with similar treatment regimens and follow-up to the treatment group. In contrast, in galileo, the placebo group received no PRN treatment until 1 year of follow-up and during the first 6 months, followup visits were bi-monthly. RESULTS: The treatment group in COPERNICUS showed a mean improvement of 13 letters versus the placebo group (1.5 letters) at week 100 of follow-up. In galileo, the mean best corrected visual acuity at 76 weeks were 13.7 and 6.6 in the treatment and placebo groups, respectively. CONCLUSIONS: Early treatment with intravitreal afliberceptin achieves better results than when treatment is delayed by 6 months or 1 year. The visual benefits obtained with the drug are affected by the reduction in the frequency of monitoring during follow-up.

[Cervical arthrodesis by means of interbody fusion with autologous bone and/or interbody spacer for cervical disc disease]. / Artrodesis cervical mediante fusión intersomática con hueso autólogo versus espaciador intersomático en discopatía cervical.

UNLABELLED: The purpose of this study was to compare the results of cervical arthrodesis performed through interbody fusion with autologous bone and/or interbody spacer for cervical disc disease. MATERIAL AND METHODS: Comparative cross-sectional study that included 49 patients who underwent surgery for anterior arthrodesis between January and December 2011, whose clinical records were reviewed. RESULTS: We included 49 patients: 20 (40.8%) males and 29 (59.2%) females. All of them were diagnosed with disc disease (cervical disc herniation) involving one or two levels. Mean operative time was 69.12, with a minimum of 53 and a maximum of 110 +/- 19.61 minutes for cervical arthrodesis with a graft. Mean operative time was 61.18 with a minimum of 50 and a maximum of 96.00 +/- 11.38 minutes for cer vical arthrodesis with an interbody spacer (p = 0.00, Student t test). Patient sociodemographic and clinical characteristics and complications are shown. Patients in whom both surgical techniques were used had appropriate radiological integration, with p = 0.015, considering p < or = a 0.05 as significant, chi2. CONCLUSIONS: In patients with cervical disc disease bone integration is appropriate with the use of either an interbody cage or an autologous iliac crest graft.

Rhegmatogenous retinal detachment treatment guidelines.

This paper outlines general guidelines following the initial diagnosis of rhegmatogenous retinal detachment. These include preoperative evaluation, treatment, possible intra- and post-operative complications, retinal re-detachment, and all therapeutic options available for each case. Treatment of the traumatic retinal detachment is also described, due to its importance and peculiarities. Treatment or prophylactic guidelines are suggested for the different types of retinal detachment described. These are based on both the experience of the ophthalmologists that have participated in preparing the guidelines, and also on evidence-based grading linked to bibliographical sources. However, these guidelines should not be interpreted as being mandatory. Given that there is a wide spectrum of options for treatment of retinal detachment, the surgeons' experience with one or other surgical technique will be of utmost importance in obtaining the best surgical result. As guidelines, they are intended as an additional aid to the surgeon during the decision-making process, with the expectation that the final choice will still be left to the surgeon's judgment and past experience.

BRAVO y CRUISE: ranibizumab en el tratamiento del edema macular secundario a oclusión de la vena de la retina / BRAVO and CRUISE: Ranibizumab for the treatment of macular edema secondary to retinal vein occlusion

Se describen los hallazgos de los estudios BRAVO y CRUISE, estudios multicéntricos y aleatorizados en pacientes con oclusión de rama venosa/vena central de la retina, en los que se compararon 3 grupos: 0,3 mg de ranibizumab, 0,5 mg de ranibizumab y placebo. Los pacientes recibieron tratamiento mensual durante 6 meses y a demanda siguiendo criterios anatómicos y funcionales, durante los siguientes 6 meses con 0,5 mg de ranibizumab. Los pacientes incluidos en el grupo control pudieron recibir tratamiento en esta segunda parte del estudio. Los resultados mostraron una mejoría significativa de agudeza visual y una mejoría anatómica en los grupos de tratamiento a partir del día 7 de la inyección de ranibizumab. El tratamiento a demanda con seguimiento mensual fue capaz de mantener las mejorías de agudeza visual conseguidas durante los primeros 6 meses de tratamiento. Los pacientes del grupo control que recibieron tratamiento a demanda a partir de los 6 meses mostraron una mejoría anatómica similar a la de los grupos de tratamiento y una menor mejoría visual(AU)

This article summarizes the results of the BRAVO and CRUISE trials, two randomized multicenter studies in patients with macular edema secondary to branch and central retinal vein occlusion, respectively. Randomization was 1:1:1 to 0.3 mg of ranibizumab, 0.5 mg of ranibizumab or placebo. Monthly injections were administered for 6 months followed by a 6-monthobservation period in which treatment on an on-demand (PRN) basis was applied with0.5 mg ranibizumab. Patients in the control group were also eligible for 0.5 mg ranibizumab treatment in the observation period. The results showed a significant anatomical and visual improvement in both treatment groups 7 days after the intravitreal injection. PRN treatment with monthly follow-up maintained the visual improvements achieved after the first 6 months of treatment. Patients in the control group who received PRN treatment after the first 6months showed an anatomical improvement similar to that in the treatment groups but less visual improvement(AU)

[BRAVO and CRUISE: ranibizumab for the treatment of macular edema secondary to retinal vein occlusion]. / BRAVO y CRUISE: ranibizumab en el tratamiento del edema macular secundario a oclusión de la vena de la retina.

This article summarizes the results of the BRAVO and CRUISE trials, two randomized multicenter studies in patients with macular edema secondary to branch and central retinal vein occlusion, respectively. Randomization was 1:1:1 to 0.3 mg of ranibizumab, 0.5 mg of ranibizumab or placebo. Monthly injections were administered for 6 months followed by a 6-month observation period in which treatment on an on-demand (PRN) basis was applied with 0.5 mg ranibizumab. Patients in the control group were also eligible for 0.5 mg ranibizumab treatment in the observation period. The results showed a significant anatomical and visual improvement in both treatment groups 7 days after the intravitreal injection. PRN treatment with monthly follow-up maintained the visual improvements achieved after the first 6 months of treatment. Patients in the control group who received PRN treatment after the first 6 months showed an anatomical improvement similar to that in the treatment groups but less visual improvement.

La vitrectomía como terapia antinflamatoria de la uveítis intermedia en niños / Pars plana vitrectomy as anti-inflammatory therapy for intermediate uveitis in children

ObjetivoLas uveítis intermedias constituyen entre el 2 y el 26% de las uveítis en niños. El curso natural es variable existiendo desde casos leves autolimitados hasta formas crónicas más severas que cursan con múltiples recurrencias y complicaciones. El objetivo de este estudio es valorar la utilidad de la vitrectomía para controlar la inflamación en niños con uveítis intermedias recurrentes.MétodosEstudio retrospectivo con seguimiento de al menos seis meses. Se incluyeron todos los niños menores de dieciséis años intervenidos mediante vitrectomía por uveítis intermedia tras haber sufrido al menos dos brotes de inflamación intermedia sin tratamiento profiláctico inmunosupresor sistémico previo a la cirugía. Se recogieron los cambios en la agudeza visual (AV), las recaídas y las complicaciones derivadas de la cirugía.ResultadosSe seleccionaron siete ojos de cinco niños con uveítis intermedia que requirieron vitrectomía. Tras un seguimiento medio de 34 meses, la AV había mejorado en todos los ojos respecto a la situación prequirúrgica. Cuatro ojos desarrollaron cataratas subcapsulares posteriores leves. Las recurrencias posquirúrgicas fueron de localización anterior y controladas con tratamiento tópico, salvo un brote de uveítis intermedia tratada con una inyección de triamcinolona periocular. Solo un niño se encuentra actualmente bajo terapia inmunosupresora sistémica, debido a la presencia de brotes de uveítis intermedia en el ojo no operado y dado que sus padres rechazaron la cirugía.ConclusiónLa vitrectomía con crioterapia inferior es una opción terapéutica a considerar para el control de la actividad inflamatoria de las uveítis intermedias en niños a medio plazo para evitar los efectos secundarios asociados a los inmunosupresores sistémicos(AU)

PurposeIntermediate uveitis represents between 2 and 26% of uveitis in children. The spectrum of the disease is highly variable, ranging between mild cases that resolve spontaneously and chronic, severe forms that develop multiple episodes and complications. The purpose of this study is to evaluate the efficacy of vitrectomy to control inflammation in children with recurrent intermediate uveitis.MethodsRetrospective evaluation of patients with at least six months of follow-up. All patients under 16 who had undergone vitrectomy for intermediate uveitis were included. Vitrectomy was performed after at least two episodes of intermediate uveitis in children that had had no previous prophylactic systemic immunosuppressant treatment. Data recorded were visual acuity (VA), recurrences and surgical complications.ResultsSeven eyes of five children with intermediate uveitis who underwent vitrectomy were included. After a mean follow-up of 34 months, VA improved in all eyes after surgery. Four eyes developed mild subcapsular posterior cataracts. Post-surgical recurrences were anterior and responded to topical treatment, except for an episode of intermediate uveitis that required a periocular injection of triamcinolone. Only one patient is being treated with systemic immunosuppressants, due to the presence of repeated episodes of uveitis in the non-vitrectomised eye and since his parents were unwilling to have him undergo new surgery.ConclusionsVitrectomy with inferior cryotheraphy controls inflammation in intermediate uveitis in children with good mid-term results avoiding the secondary side-effects of systemic immunosuppressants(AU)

Results of bevacizumab as the primary treatment for retinal vein occlusions.

BACKGROUND: The purpose of this study is to evaluate the efficacy of intravitreal bevacizumab as the primary treatment of macular oedema due to retinal vein occlusions. METHODS: Patients diagnosed as having central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) with visual acuity of less than 20/40 and macular oedema with more than 300 microm central retinal thickness were recruited. Patients that had received any prior treatment were excluded. After an initial intravitreal injection of bevacizumab, re-treatment was performed if intraretinal or subretinal fluid with distortion of the foveal depression was found in optical coherence tomography. RESULTS: 18 eyes with CRVO and 28 eyes with BRVO were included. During a 6-month period, the mean number of injections per patient was 3.7 (BRVO group) and 4.6 (CRVO group). In the BRVO group, mean baseline logMAR visual acuity was 0.80 (SD 0.38) and macular thickness was 486.9 microm (SD 138.5 microm). After 6 months, mean logMAR visual acuity improved significantly to 0.44 (SD 0.34), p<0.001. Mean macular thickness decreased significantly to 268.2 microm (SD 62.5 microm), p<0.001. In the CRVO group, mean baseline logMAR visual acuity was 1.13 (SD 0.21) and macular thickness was 536.4 microm (SD 107.1 microm). Mean final logMAR visual acuity improved significantly to 0.83 (SD 0.45), p<0.001. Mean macular thickness decreased significantly to 326.17 microm (SD 96.70 microm), p<0.001. CONCLUSIONS: Intravitreal bevacizumab seems to be an effective primary treatment option for macular oedema due to retinal occlusions. Its main drawback is that multiple injections are necessary to maintain visual and anatomic improvements.

[Anatomical and functional outcomes of vitrectomy for the treatment of pseudophakic regmatogenous retinal detachment]. / Resultados anatómicos y funcionales de la vitrectomía aislada en el tratamiento del desprendimiento de retina regmatógeno pseudofáquico.

PURPOSE: To report the results obtained in a non-comparative series of pseudophakic patients with retinal detachment (RD) treated with vitrectomy with no associated scleral procedures. METHODS: The clinical records of all pseudophakic patients with RD treated with vitrectomy were evaluated by one of the authors. Patients with primary regmatogenous RD with no signs of proliferative vitreoretinopathy were included. Patients with associated ocular pathologies or with less than 3 months follow-up were excluded. Main outcome measures were anatomical reattachment rate after one surgery, visual acuity change and surgical complications. The surgical procedure consisted of 20 g pars plana vitrectomy, with removal of peripheral vitreous up to the ora serrata. Laser photocoagulation of all retinal breaks was performed and 14% C3F8 was used as tamponade. RESULTS: Thirty-one patients were included in the study. In 18 patients the macula was affected. Mean follow-up was 6.45 months (range 3 to 18). Retinal reattachment was achieved in all patients and only one patient experienced a re-detachment, 3 months after surgery. Visual acuity improved by a mean of 2.5 Snellen lines and 61.3% of patients reached a final visual acuity of 0.5 or better. Eight patients had an intraocular pressure rise after surgery, which was controlled with topical medication. No other complications were recorded. DISCUSSION: Our results support the hypothesis that vitrectomy alone is a useful technique for the treatment of RD in pseudophakic eyes.

Resultados anatómicos y funcionales de la vitrectomía aislada en el tratamiento del desprendimiento de retina regmatógeno pseudofáquico / Anatomical and functional outcomes of vitrectomy for the treatment of pseudophakic regmatogenous retinal detachment

Objetivo: Comunicar los resultados obtenidos en una serie no comparativa de pacientes pseudofáquicos con desprendimiento de retina (DR) tratados con vitrectomía, sin procedimientos esclerales asociados.Métodos: Estudio retrospectivo de pacientes con DR pseudofáquicos tratados con vitrectomía aislada por uno de los autores. Se incluyó a pacientes con DR regmatógeno primario sin signos de proliferación vitreorretiniana. Se excluyó a aquellos con otras patologías oculares asociadas o con menos de 3 meses de seguimiento. Los principales datos evaluados fueron la tasa de reaplicación anatómica, el cambio en agudeza visual y la incidencia de complicaciones.La técnica quirúrgica consistió en una vitrectomía 20 g vía pars plana, con eliminación del vítreo periférico hasta la ora serrata. Se realizó fotocoagulación con láser de las roturas retinianas identificadas, empleándose C3F8 al 14% como taponador. Resultados: Treinta y un pacientes fueron incluidos. Dieciocho pacientes presentaban afectación macular al diagnóstico. El tiempo medio de seguimiento fue de 6,45 meses (rango: 3-18). Se consiguió la reaplicación anatómica en todos los ojos; un único paciente desarrolló un re-desprendimiento a los 3 meses de la cirugía. La agudeza visual mejoró una media de 2,5 líneas de Snellen, con una agudeza visual final mejor de 0,5 en un 61,3% de los pacientes. Ocho pacientes presentaron un incremento de la presión intraocular tras la cirugía, controlada con hipotensores tópicos. No se detectaron otras complicaciones.Discusión: Nuestros resultados apoyan la hipótesis de que la vitrectomía aislada es una técnica quirúrgica útil para el tratamiento del DR en ojos pseudofáquicos(AU)

Purpose: To report the results obtained in a non-comparative series of pseudophakic patients with retinal detachment (RD) treated with vitrectomy with no associated scleral procedures.Methods: The clinical records of all pseudophakic patients with RD treated with vitrectomy were evaluated by one of the authors. Patients with primary regmatogenous RD with no signs of proliferative vitreoretinopathy were included. Patients with associated ocular pathologies or with less than 3 months follow-up were excluded. Main outcome measures were anatomical reattachment rate after one surgery, visual acuity change and surgical complications.The surgical procedure consisted of 20 g pars plana vitrectomy, with removal of peripheral vitreous up to the ora serrata. Laser photocoagulation of all retinal breaks was performed and 14% C3F8 was used as tamponade.Results: Thirty-one patients were included in the study. In 18 patients the macula was affected. Mean follow-up was 6.45 months (range 3 to 18). Retinal reattachment was achieved in all patients and only one patient experienced a re-detachment, 3 months after surgery.Visual acuity improved by a mean of 2.5 Snellen lines and 61.3% of patients reached a final visual acuity of 0.5 or better. Eight patients had an intraocular pressure rise after surgery, which was controlled with topical medication. No other complications were recorded.Discussion: Our results support the hypothesis that vitrectomy alone is a useful technique for the treatment of RD in pseudophakic eyes(AU)

[Pars plana vitrectomy as anti-inflammatory therapy for intermediate uveitis in children]. / La vitrectomía como terapia antinflamatoria de la uveítis intermedia en niños.

PURPOSE: Intermediate uveitis represents between 2 and 26% of uveitis in children. The spectrum of the disease is highly variable, ranging between mild cases that resolve spontaneously and chronic, severe forms that develop multiple episodes and complications. The purpose of this study is to evaluate the efficacy of vitrectomy to control inflammation in children with recurrent intermediate uveitis. METHODS: Retrospective evaluation of patients with at least six months of follow-up. All patients under 16 who had undergone vitrectomy for intermediate uveitis were included. Vitrectomy was performed after at least two episodes of intermediate uveitis in children that had had no previous prophylactic systemic immunosuppressant treatment. Data recorded were visual acuity (VA), recurrences and surgical complications. RESULTS: Seven eyes of five children with intermediate uveitis who underwent vitrectomy were included. After a mean follow-up of 34 months, VA improved in all eyes after surgery. Four eyes developed mild subcapsular posterior cataracts. Post-surgical recurrences were anterior and responded to topical treatment, except for an episode of intermediate uveitis that required a periocular injection of triamcinolone. Only one patient is being treated with systemic immunosuppressants, due to the presence of repeated episodes of uveitis in the non-vitrectomised eye and since his parents were unwilling to have him undergo new surgery. CONCLUSIONS: Vitrectomy with inferior cryotheraphy controls inflammation in intermediate uveitis in children with good mid-term results avoiding the secondary side-effects of systemic immunosuppressants.

Inferior sclerotomies without subretinal fluid drainage for exudative retinal detachment in diffuse retinal pigment epitheliopathy.

PURPOSE: To evaluate the efficacy of inferior sutureless sclerotomies without subretinal fluid drainage for the treatment of bullous exudative retinal detachment secondary to diffuse retinal pigment epitheliopathy. METHODS: A retrospective interventional case series of eyes treated with two inferior postequatorial full-thickness sclerotomies without subretinal fluid drainage. Patients were placed in an upright position 24 hours after surgery. Main outcomes were visual acuity and retinal reattachment rate. RESULTS: Three eyes with recent diagnoses of diffuse retinal pigment epitheliopathy and bullous inferior retinal detachment were included in the study. In all cases, a very thick sclera was evident during surgery. The day after surgery the retina was completely attached in the three eyes. Preoperative visual acuity was light perception, 20/200, and counting fingers. After surgery, visual acuity improved to 20/200, 20/70, and 20/50, respectively. No intra- or postoperative complications occurred. CONCLUSIONS: The performance of inferior sutureless sclerotomies without a draining procedure in cases of diffuse retinal pigment epitheliopathy with inferior bullous retinal detachment is a simple and effective technique. It achieves retinal reattachment the day after surgery, allowing laser photocoagulation of the leaking lesions disclosed in fluorescein angiography.

[Evaluation of trypan-blue toxicity in macular hole surgery with electroretinography]. / Evaluación mediante electrorretinografía de la toxicidad del azul tripán en la cirugía del agujero macular.

PURPOSE: Concern has been raised about the retinal toxicity of vital dyes. We designed a prospective study to determine the possible toxicity of trypan-blue (TB) in macular hole surgery with TB-assisted internal limiting membrane (ILM) peeling through the performance of electroretinograms (ERGs). METHODS: Patients diagnosed with a macular hole underwent ophthalmological evaluation prior to surgery and at 6 months follow-up. All patients underwent vitrectomy and ILM-staining under air. All phakic patients underwent phacoemulsification and IOL implantation simultaneously. There were two study groups: In group 1, ILM-staining was performed with 0.06% TB, while in group 2 the procedure was performed with 0.15% TB. Preoperative ERG recordings were measured in the week prior to surgery. Postoperative ERGs were measured 3 to 6 months after surgery. The ERG data between eyes with macular hole and fellow eyes were compared in the pre- and post-operative stages. Visual acuity (VA) changes in both groups were evaluated. RESULTS: Nine patients were recruited in each group. VA improved significantly in both groups, with more than 65% of patients improving more than 2 lines. There were no statistical differences in VA gain between groups or in ERG values between affected and fellow eyes. CONCLUSION: No significant retinal toxicity of TB staining could be clinically detected.

Treatment of peripapillary choroidal neovascular membranes with intravitreal bevacizumab.

AIMS: To evaluate the effect of intravitreal injections of bevacizumab in the treatment of peripapillary choroidal neovascular membranes. METHODS: Interventional case series of patients with active peripapillary choroidal neovascular membranes. Ophthalmological examination included best-corrected visual acuity, fundus biomicroscopy, fluorescein angiography and optical coherence tomography (OCT). Bevacizumab injections (1.25 mg) were repeated monthly for the first 3 months. Re-treatment was considered if there were any signs of membrane activity. RESULTS: Six eyes of five patients with peripapillary choroidal membranes were included in the study with a mean follow-up of 13 months (range 6 to 16). Bevacizumab was used as the initial treatment in four eyes and to manage recurrences after surgery in the other two. In five eyes, three injections of bevacizumab led to a complete resolution of leakage on fluorescein angiography and OCT. In one eye, membrane activity persisted despite six injections of bevacizumab. Visual acuity improved in five eyes with a mean improvement of four lines (range: 2-10 lines). It deteriorated only in the eye that did not respond to treatment. CONCLUSIONS: The results of this case series suggest that the intravitreal injection of bevacizumab may be an effective treatment for peripapillary choroidal membranes.